• KOL
    • KOLs Community
    • Type
    • Type 2
    • Type 2 Diabetes
    • Hajime Izumiyama
    • Hajime Izumiyama

      Hajime Izumiyama

      Center for Medical Welfare and Liaison Services, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510, Japan. | Department of Molecular Endocrinology and Metabolism, ...

       

       

      KOL Resume for Hajime Izumiyama

      Year
      2019

      Center for Medical Welfare and Liaison Services, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510, Japan.

      2018

      Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.

      2017

      Center for Medical Welfare and Liaison Services, Tokyo Medical and Dental University

      2016

      Center for Medical Welfare and Liaison Services, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510 Japan

      2015

      Department of Molecular Endocrinology and MetabolismGraduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, JapanDepartment of Maternal-Fetal BiologyNational Research Institute for Child Health and Development, Tokyo 157-8535, JapanCenter for Medical Welfare and Liaison ServicesDepartments of UrologyPreemptive Medicine and MetabolismOrgan Network and MetabolismGraduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, JapanJapan Science and Technology AgencyPRESTO, Tokyo 102-0076, JapanJapan Science and Technology AgencyCREST, Tokyo 102-0076, Japan Department of Molecular Endocrinology and MetabolismGraduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, JapanDepartment of Maternal-Fetal BiologyNational Research Institute for Child Health and Development, Tokyo 157-8535, JapanCenter for Medical Welfare and Liaison ServicesDepartments of UrologyPreemptive Medicine and MetabolismOrgan Network and MetabolismGraduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, JapanJapan Science and Technology AgencyPRESTO, Tokyo 102-0076, JapanJapan Science and Technology AgencyCREST, Tokyo 102-0076, Japan.

      Center for Medical Welfare and Liaison Services, Tokyo Medical and Dental University, 113-8510, Tokyo, Japan

      2013

      Tokyo Medical and Dental University Medical Hospital, Tokyo, Japan

      2012

      Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School

      Tokyo Medical and Dental University Medical Hospital

      2011

      Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School, Japan

      Clinical and Molecular Endocrinology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University

      2005

      Department of Clinical and Molecular Endocrinology Tokyo Medical and Dental University Graduate School

       

       

      Hajime Izumiyama: Influence Statistics

      Sample of concepts for which Hajime Izumiyama is among the top experts in the world.
      Concept World rank
      acth nfa #3
      presence salusins #3
      chapter 193 salusins #3
      salusins discovered #3
      isoforms acth #3
      prosalusin variety #3
      unprocessed biologically #3
      pomc sca #3
      nfas immunohistochemical study #3
      characteristics isolation discovery #3
      unidentified ligands characteristics #3
      sca neoplastic humans #3
      antiacth antibody differences #3
      physicochemical property polypropylene #3
      inactive pomc #3
      salusinβ peptide #3
      bioactivity salusin #3
      193 salusins #3
      remaining nfa #3
      preferential production sca #3
      6 scas data #3
      bioactivity salusinβ #3
      6 scas #3
      parasympathomimetic actions attempts #3
      positive acth immunoreactivity #3
      salusins contrasting activities #3
      potent hemodynamic effects #3
      sca lead #3
      clinical endocrine feartures #3
      pigmentation 88 #4
      hypokalemia 88 #4
      88 skin pigmentation #4
      unknown eas #4
      corticotroph sca #4
      laterality avs #4
      proven eas #4
      avs laterality #4
      japan ectopic #4
      hypersecretion skin #4
      skin pigmentation 88 #4
      75 acth #4
      occult unknown #4
      occult unknown eas #4
      hypersecretion pa #4
      neurod1 ikzf1 #5
      receptors acth secretion #5
      crhr1 vasopressin #5
      metyrapone tumor #5
      neurod1 eas #5
      plasma office #5

       

      Prominent publications by Hajime Izumiyama

      KOL-Index: 14690

      BACKGROUND: Abdominal visceral obesity has been reported to be associated with cardiovascular risks than body mass index, waist circumference, and abdominal subcutaneous fat. On the other hand, there is evidence that subcutaneous fat has a beneficial role against cardio-metabolic risks such as diabetes or dyslipidemia. However, little is known regarding the association between high visceral fat with low subcutaneous fat accumulation and the risk for atherosclerosis.

      METHODS: This study ...

      Known for Visceral Fat | Type 2 Diabetes | Atherosclerosis Patients | Vfa ≥ | 2 Female
      KOL-Index: 13361

      OBJECTIVE: Differential expression of several genes between ACTH-secreting pituitary tumors causing Cushing' disease (CD), silent corticotroph adenoma (SCA), and non-functioning pituitary tumors (NFT) was investigated.

      DESIGN AND METHODS: We used tissue specimens from 35 pituitary tumors (12 CD, 8 SCA, and 15 NFT). Steady-state mRNA levels of the genes related to proopiomelanocortin (POMC) transcription, synthesis, processing, and secretion, such as neurogenic differentiation 1 ...

      Known for Gene Expression | Sca Nft | Messenger Receptors | Functioning Pituitary | Acth Secreting
      KOL-Index: 12038

      BackgroundAccumulation of epicardial fat (EF) is associated with increased cardio-metabolic risks and coronary events, independently of traditional cardiovascular risk factors. Therefore, the reduction of EF volume (EFV) may be associated with reduced cardio-metabolic risks and future cardiovascular events. Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce body fat including visceral fat and cardiovascular events in patients with type 2 diabetes. However, it has still been ...

      Known for Type 2 | Epicardial Fat | Luseogliflozin Treatment | Vfa Lai | Body Weight Bmi
      KOL-Index: 11052

      The purpose of this study was to examine whether periodontal treatment incorporating topical antibiotic therapy affects on levels of glycohemoglobin (HbA1c) and serum high-sensitivity C-reactive protein (hs-CRP) in type 2 diabetic patients with periodontal disease, and to explore the relationship between CRP and glycemic control. The whole intervention group (n=32), which underwent anti-infectious periodontal treatment, showed only transient reduction in HbA1c levels without any change ...

      Known for Periodontal Treatment | Type 2 | Diabetic Patients | Reduction Hba1c | Intervention Study
      KOL-Index: 10659

      BACKGROUND: Whole body dual-energy X-ray absorptiometry (DXA) can simultaneously measure both regional fat and non-fat mass. Android-to-gynoid (A/G) ratio measured by DXA has been reported to be associated with cardiovascular risks and visceral adiposity; however, little is known regarding its relationship with fatty liver disease and atherosclerosis among patients with diabetes. This study was designed to investigate the association of android and gynoid fat mass measured by DXA with ...

      Known for Type 2 | Fatty Liver | Fat Mass | Ray Absorptiometry | Vfa Lai
      KOL-Index: 10547

      OBJECTIVE: Among indirect measures of visceral adiposity, A Body Shape Index (ABSI), which is defined as waist circumference (WC)/(body mass index (BMI)(2/3)×height(1/2)), is unique in that ABSI is positively correlated with visceral adiposity and is supposed to be independent of BMI. ABSI has been also shown to be linearly and positively associated with visceral fat mass and all-cause and cardiovascular disease (CVD) in the general population. It is, however, uncertain whether ABSI ...

      Known for Arterial Stiffness | Visceral Adiposity | Type 2 Diabetes | Bmi Absi | Body Shape
      KOL-Index: 10203

      Sarcopenia is defined as an age-related loss of skeletal muscle mass and strength, and is a major cause of disability and mobility limitations. Recent studies have demonstrated that type 2 diabetes and insulin signaling deficiencies contribute to the progression of sarcopenia, suggesting that a sufficient supply of insulin to the skeletal muscles may be important for the maintenance of muscle function; however, little has been reported regarding whether insulin treatment can protect ...

      Known for Insulin Treatment | Type 2 Diabetes | Muscle Mass | Sarcopenia Patients | Grip Strength
      KOL-Index: 9603

      Liraglutide, an analogue of human glucagon-like peptide 1, reduces cardiovascular events in patients with type 2 diabetes; however, it has still been unknown by which mechanisms liraglutide could reduce cardiovascular events. Type 2 diabetic patients with insulin treatment were enrolled in this randomized, open-label, comparative study. Participants were randomly assigned to liraglutide plus insulin (liraglutide group) and insulin treatment (control group) at 1:1 allocation. Primary ...

      Known for Type 2 | Visceral Fat | Hepatic Steatosis | Liraglutide Treatment | Cardiovascular Events
      KOL-Index: 9466

      AIMS/INTRODUCTION: To investigate whether the ratio of visceral fat area (VFA) to subcutaneous fat area (SFA; V/S ratio) could be predictive of cardiovascular disease (CVD) as compared with VFA or SFA in patients with diabetes.

      MATERIALS AND METHODS: A total of 682 patients with type 2 diabetes (mean age 64 ± 13 years; 41% women) were enrolled. VFA (cm2 ) and SFA (cm2 ) were assessed by a dual bioelectrical impedance analyzer. The patients were divided into four groups according to the ...

      Known for Type 2 Diabetes | Vfa Sfa | Subcutaneous Fat | Cardiovascular Events | Cvd Patients
      KOL-Index: 9195

      AIM: Endothelial dysfunction is considered an early event in the development of atherosclerosis. The present study was undertaken to determine whether the accumulation of cardiovascular risk factors and insulin resistance are associated with endothelial function in diabetic patients.

      METHODS: 101 patients with type 2 diabetes without macroangiopathy stratified by the number of cardiovascular risk factors (dyslipidemia, hypertension, obesity) and 9 normal control subjects were studied for ...

      Known for Insulin Resistance | Endothelial Dysfunction | Diabetic Patients | Type 2 Endothelium | Cardiovascular Risk Factors
      KOL-Index: 8868

      Measurement of late-night and/or midnight salivary cortisol currently used in US and European countries is a simple and convenient screening test for the initial diagnosis of Cushing's syndrome (CS). Unfortunately, this test has not been widely used in Japan. The purpose of this study was to evaluate the usefulness of the measurement of late-night salivary cortisol as a screening test for the diagnosis of CS in Japan. We studied 27 patients with various causes of CS, consisting of ...

      Known for Salivary Cortisol | Screening Test | Normal Subjects | Cushings Syndrome | Diagnosis Cushing
      KOL-Index: 8734

      OBJECTIVES: Chronic inflammation of periodontitis aggravates glycemic control in type 2 diabetic patients through aggravation of insulin resistance. Increased or decreased release of various inflammatory mediators, such as high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor (TNF)-α, interleukin (IL)-6 and adipokines, such as adiponectin, leptin, and resistin, are presumed to be responsible for developing and progressing insulin resistance. The purpose of this study was to ...

      Known for Periodontal Treatment | Glycemic Control | Type 2 | Insulin Resistance | Adiponectin Patients
      KOL-Index: 8733

      A 75-year-old woman was admitted to our hospital because of a poor glycemic control. She was found to have Cushingoid feature and dynamic endocrine tests showed elevated plasma ACTH and cortisol levels, lack of their circadian rhythm, non-suppressibility to high-dose dexamethasone, responsiveness to CRH, but not to DDAVP, and suppression to octreotide. Pituitary MRI showed an equivocal small lesion. CT scan of the chest showed two nodular lesions in the right lung (S5, S7), while a mild ...

      Known for Ectopic Acth Syndrome | Carcinoid Tumor | Cushing Disease | Fluorodeoxyglucose F18 | Cortisol Levels
      KOL-Index: 8006

      Primary aldosteronism (PA), an autonomous aldosterone hypersecretion from adrenal adenoma and/or hyperplasia, and subclinical Cushing syndrome (SCS), a mild but autonomous cortisol hypersecretion from adrenal adenoma without signs or symptoms of Cuhing's syndrome, are now well-recognized clinical entities of adrenal incidentaloma. However, the clinicopathological features of PA associated with SCS (PA/SCS) remain unknown. The present study was undertaken to study the prevalence of PA/SCS ...

      Known for Pa Scs | Primary Aldosteronism | Adrenal Adenoma | Subclinical Cushing | Aldosterone Hypersecretion
      KOL-Index: 7880

      Flow-mediated vasodilatation (FMD) is a vascular functional test to detect endothelial dysfunction at the early stage of cardiovascular diseases. Patients with active acromegaly have higher morbidity and mortality due to cardiovascular events. To determine whether active acromegaly is associated with endothelial dysfunction, we studied 17 patients with active acromegaly for measurements of FMD, carotid intima-media thickness (IMT) and brachial-ankle pulse wave velocity (baPWV), and other ...

      Known for Endothelial Dysfunction | Active Acromegaly | Fmd Patients | Insulin Growth | Cardiovascular Diseases

      Key People For Type 2 Diabetes

      Top KOLs in the world
      #1
      David Richard Matthews
      type 2 diabetes sri lanka growth hormone
      #2
      Frank B Hu
      type 2 diabetes cardiovascular disease physical activity
      #3
      Rury R Holman
      type 2 diabetes cardiovascular disease impaired glucose tolerance
      #4
      David Matthew Nathan
      type 2 diabetes insulin resistance cardiovascular disease
      #5
      John B Buse
      type 2 diabetes insulin degludec cardiovascular outcomes
      #6
      Tuomilehto Tuomilehto
      type 2 diabetes blood pressure north karelia

      Hajime Izumiyama:Expert Impact

      Concepts for whichHajime Izumiyamahas direct influence:Type 2 diabetes,  Type 2,  Periodontal treatment,  Endothelial dysfunction,  Insulin treatment,  Visceral fat,  Visceral adiposity,  2 diabetes.

      Hajime Izumiyama:KOL impact

      Concepts related to the work of other authors for whichfor which Hajime Izumiyama has influence:Type 2 diabetes,  Primary aldosteronism,  Periodontal treatment,  Glycemic control,  Cushing syndrome,  Arterial stiffness,  Muscle mass.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      Center for Medical Welfare and Liaison Services, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510, Japan. | Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental U

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.